Products
Gadobuscan®
Pharmacotherapeutic group
MRI contrast agentInternational name
GadobutrolDosage form
intravenous solutionGadobuscan® is a paramagnetic contrast agent for magnetic resonance imaging.
Image contrast enhancement is due to its active component gadobutrol, which is a neutral (nonionic) complex of gadolinium (III) with a macrocyclic ligand - dihydroxy-hydroxymethylpropyltetraazacyclododecane-triacetic acid (butrol).
When T1-weighted pulse sequences are used in magnetic resonance studies, the shortening of spin-lattice relaxation time of excited atomic nuclei induced by gadolinium ions leads to an increase in signal intensity and, as a result, to an increase in the contrast of images of certain tissues. However, when using T2*-weighted sequences, the induction of local nonhomogeneity of the magnetic field under the influence of the strong magnetic moment of gadolinium at its high concentration (bolus administration) leads to a decrease in the signal.
Gadobutrol even at low concentrations causes a significant shortening of relaxation times. The ability to alter the relaxation times T1 and T2, as determined by the effect on the spin-lattice and spin-spin relaxation times of protons in plasma at pH 7 and 40°C, is approximately 5.6 l/mmol*s and 6.5 l/mmol*s, respectively. The ability to affect the relaxation time is only slightly dependent on the magnetic field strength.
No inhibition of enzyme activity was detected by gadobutrol.
Image contrast enhancement is due to its active component gadobutrol, which is a neutral (nonionic) complex of gadolinium (III) with a macrocyclic ligand - dihydroxy-hydroxymethylpropyltetraazacyclododecane-triacetic acid (butrol).
When T1-weighted pulse sequences are used in magnetic resonance studies, the shortening of spin-lattice relaxation time of excited atomic nuclei induced by gadolinium ions leads to an increase in signal intensity and, as a result, to an increase in the contrast of images of certain tissues. However, when using T2*-weighted sequences, the induction of local nonhomogeneity of the magnetic field under the influence of the strong magnetic moment of gadolinium at its high concentration (bolus administration) leads to a decrease in the signal.
Gadobutrol even at low concentrations causes a significant shortening of relaxation times. The ability to alter the relaxation times T1 and T2, as determined by the effect on the spin-lattice and spin-spin relaxation times of protons in plasma at pH 7 and 40°C, is approximately 5.6 l/mmol*s and 6.5 l/mmol*s, respectively. The ability to affect the relaxation time is only slightly dependent on the magnetic field strength.
No inhibition of enzyme activity was detected by gadobutrol.
LEAVE A FEEDBACK
We care about the consumers health and our medicines.
Данный сайт содержит информацию о лекарственных препаратах, отпускаемых по рецепту.
В соответствии со статьей 67 Федерального закона от 12.04.2010 № 61-ФЗ «Об обращении лекарственных средств» материалы данного сайта предназначены (и могут быть доступны) исключительно для медицинских и фармацевтических работников. АО «Фармасинтез» не несет ответственность за возможные негативные последствия, возникшие в результате использования информации данного сайта без предварительной консультации со специалистом лицами, не являющимися медицинскими и фармацевтическими работниками.
В соответствии со статьей 67 Федерального закона от 12.04.2010 № 61-ФЗ «Об обращении лекарственных средств» материалы данного сайта предназначены (и могут быть доступны) исключительно для медицинских и фармацевтических работников. АО «Фармасинтез» не несет ответственность за возможные негативные последствия, возникшие в результате использования информации данного сайта без предварительной консультации со специалистом лицами, не являющимися медицинскими и фармацевтическими работниками.
Choose who you are: